TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Bowel symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: IBS-quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportions of CALs during the convalescent phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of prostate cancer detected on biopsy
Endpoint domain: Mortality/survival
Primary endpoint: Rate of acute urinary retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Compliance with asthma management quality indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximum heart rate during the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of time heart rate was more than 1 standard deviation above mean for age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arterial oxygen saturation dropped below 90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnostic accuracy of EUS-EB compared to EUS-FNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PASI75 response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in A1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of rehospitalizations
Endpoint domain: Adverse events/effects
Primary endpoint: Drug cost per patient day
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in facial laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bond strength to caries-affected dentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difficulties in advanced mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: freedom from rejection
Endpoint domain: Mortality/survival
Primary endpoint: Sustained improvement in mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hot flash frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin infections
Endpoint domain: Adverse events/effects
Primary endpoint: Ischemic stroke incidence
Endpoint domain: Mortality/survival
Primary endpoint: Increase in measured AS parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean morning plasma cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Recovery from depression symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Endothelial activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Kidney function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 1-year graft survival rates
Endpoint domain: Mortality/survival
Primary endpoint: recovery time for graft function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of cilostazol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of cilostazol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2z of cilostazol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse effect profile
Endpoint domain: Adverse events/effects
Primary endpoint: T-wave alternans values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: right ventricle diastolic diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: estimated systolic pulmonary artery pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximum renal tubular threshold for phosphate reabsorption (TmP/GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: serum Pi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum 1,25(OH)2D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pain Rating Scale (PRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rapid absorption of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations correlating with pharmacodynamic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of the formulation
Endpoint domain: Adverse events/effects
Primary endpoint: Spontaneous reversion to sinus rhythm (SR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maintenance of sinus rhythm (SR) at 8 weeks following DCCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maintenance of sinus rhythm (SR) at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in CD4 count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients achieving viral suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient ED recalls
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Short-term inpatient bed days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patent ductus arteriosus closure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cystatin-C level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in self-esteem scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: C3 concentration change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: FFA response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Capacitance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: early deaths
Endpoint domain: Mortality/survival
Primary endpoint: sudden late deaths
Endpoint domain: Mortality/survival
Primary endpoint: valve thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: valve dysfunctions
Endpoint domain: Adverse events/effects
Primary endpoint: peripheral arterial emboli
Endpoint domain: Adverse events/effects
Primary endpoint: percent time awake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rapid eye movement sleep bouts per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of AOM episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: tolerance to cutaneous stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cosmetic results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ad libitum energy intake after video game play
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Timing of complementary food introduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of pruritus
Endpoint domain: Adverse events/effects
Primary endpoint: early seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: late seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: risk of posttraumatic epilepsy (PTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean BMI95 reduction at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bowel sound recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gas passage time by anus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Tissue Oxygenation (Ptco2/Fio2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost-related difficulty in accessing mammography
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean postoperative length of stay (LOS)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean number of midazolam boluses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Chronic pain (VAS score >3)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rates of remission at 28 weeks
Endpoint domain: Mortality/survival
Primary endpoint: body structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: activities participation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: self‐perception
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of live births
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Attention dimension of cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Newcastle Satisfaction with Nursing Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fetal movement counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Fetal heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Incidence of procedure-related serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: STREAM scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motor FIM scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symmetry ratio‐swing time of the paretic leg/swing time of non‐paretic leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bioavailable IGF-I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: urea/creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endoscopic mucosa healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: stain reduction scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: observed verbal indicators of injection pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death, myocardial infarction, or recurrent cardiac hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: apoA‐II concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LpA‐I particles concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rectal bleeding score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: stool frequency score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Knowledge of sublingual nitroglycerin
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Responder rate for SPG neuromodulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC for NRS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Avoidance of opioid rescue medication
Endpoint domain: Adverse events/effects
Primary endpoint: Median time-to-first-opioid use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial clinical success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained clinical improvement after 43 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of remission during acute ECT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse rates with continuation pharmacotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse rates with continuation ECT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic effect in RA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement by day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance of anticytokines
Endpoint domain: Adverse events/effects
Primary endpoint: sTREM2 in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: IL6 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IFNγ concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Δ 24‐h systolic ABPM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Δ estimated glomerular filtration rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of patients requiring additional boluses of ropivacaine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Responsiveness to bradykinin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Grade 2 or greater bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Posttransfusion platelet count increments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean blood component use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: first-attempt success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Abdominal distension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: PRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GMFM score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for cervical intraepithelial neoplasia of grade 2 or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Positive predictive value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of unsatisfactory results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fibrosis progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physical consequences attributed to alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thyroid status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Levels of acylcarnitines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average root canal preparation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: emergence times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cost for consumed anaesthetics
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: incidence of clinically significant bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: VAS-measured pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 AUC0‐12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ever tested for HIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: DAS28 <2.6 rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean high‐sensitivity C‐reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of coronary calcification (CC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severity of aortic calcification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: procedure suspension due to pain
Endpoint domain: Adverse events/effects
Primary endpoint: Increase of F1+2 after relocation of the hip joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Increase in FPA during implantation of the femoral component
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean time to demand for postoperative analgesic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median morphine consumption in 24 h after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recall for assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Thickness of AS plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance of clinical trials
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Need for axillary dissection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: central systolic BP (cSBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: brachial systolic BP (bSBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: brachial diastolic BP (bDBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: improvements in trough FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: incidence of TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: discontinuation due to TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: TFV/FTC hair concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Doses measured in hands and left knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion delineation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Image quality estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean time to haemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean blood loss during the operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean blood loss after cross-clamp removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sub‐syndromal symptoms duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reorganization of EEG/MEG microstructure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain relief from infiltration and cryotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial Performance Index (MPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean BPRS Agitation Factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects rated as improved on the CGI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased hospital days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Systolic blood pressure difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic blood pressure difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Faster reaction times on the KiTAP go/no-go task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fewer distractibility errors of omission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in hyperactivity inattention on Strengths and Difficulties Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lower night-time SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Greater likelihood of nocturnal dipping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: lymph node yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: GH-2000 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IGF1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P-III-P
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WTP (percentage of monthly income)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: TTO (h per day)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PDI
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Scheduled or had a Pap test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anorectal angle difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes